Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HiFiBiO Forms JV to Develop Novel Cancer Research

publication date: Dec 10, 2018

HiFiBiO Therapeutics, a Boston-Paris-Shanghai company, has formed an immune modulation JV, Victa Biotherapeutics, with Vikas P. Sukhatme, MD. Using Dr. Sukatme's research, the JV will develop drug candidates based on myeloid-derived suppressor cells (MDSCs). HiFiBiO will apply its single-cell profiling expertise to identify first-in-class antibodies for various cancer indications. HiFiBiO develops novel antibody drugs that treat cancer and autoimmune disorders. Victa has an option to license IP for any candidates that show promise as therapies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital